The Zhitong Finance App learned that CICC published a report stating that it maintained its 2024 and 2025 profit forecasts for Kangfang Biotech (09926.HK) and maintained a “outperforming industry” rating. Based on the DCF model, the bank maintained a target price of HK$90.00. According to reports, on October 16, the company announced the detailed PFS and OS double positive results of the Phase III clinical study (AK104-303/COMPASSION-16) of cardonilizumab (AK104) compared placebo plus platinum-containing chemotherapy with/without bevacizumab to treat 1L of persistent, recurrent, or metastatic cervical cancer at the same time as the 2024 Global Conference and “The Lancet”.

Zhitongcaijing · 10/17 01:25
The Zhitong Finance App learned that CICC published a report stating that it maintained its 2024 and 2025 profit forecasts for Kangfang Biotech (09926.HK) and maintained a “outperforming industry” rating. Based on the DCF model, the bank maintained a target price of HK$90.00. According to reports, on October 16, the company announced the detailed PFS and OS double positive results of the Phase III clinical study (AK104-303/COMPASSION-16) of cardonilizumab (AK104) compared placebo plus platinum-containing chemotherapy with/without bevacizumab to treat 1L of persistent, recurrent, or metastatic cervical cancer at the same time as the 2024 Global Conference and “The Lancet”.